Literature DB >> 10411130

Inosine and N1-methylinosine within a synthetic oligomer mimicking the anticodon loop of human tRNA(Ala) are major epitopes for anti-PL-12 myositis autoantibodies.

H F Becker1, Y Corda, M B Mathews, J L Fourrey, H Grosjean.   

Abstract

Sera of some patients afflicted with the inflammatory disease myositis contain antibodies of the anti-PL-12 type. A fraction of these polyclonal autoantibodies specifically precipitates the fully matured human tRNA(Ala) bearing the anticodon IGC (PL-12 antigen). Earlier work (Bunn & Mathews, 1987, Science 238:116-119) had shown that the epitopes are located entirely within the anticodon stem-loop of the tRNA(Ala). Here we demonstrate that human anti-tRNA(Ala) autoantibodies immunoprecipitate a synthetic polyribonucleotide containing inosine (I) and N1-methylinosine (m1I) separated by 2 nt as in the anticodon stem-loop of human tRNA(Ala). The shortest polyribonucleotide that can be immunoprecipitated corresponds to the pentanucleotide IpGpCpm1IpUp, which corresponds to part of the anticodon loop of human tRNA(Ala) and lacks the stem-loop structure. The efficiency of immunoprecipitation was about four times greater with longer polyribonucleotides capable of forming a stem-loop structure, and was abolished by altering the relative positions of I and m1I within the synthetic polynucleotide. Synthetic oligodeoxyribonucleotide analogs of the tRNA(Ala) stem-loop, containing the sequence dIpdGdCdm1Ip, are not antigenic. Our results show that human anti-tRNA(Ala) autoantibodies selectively recognize chemical details of modified nucleotides (the 6-keto group of inosine-34 and the 6-keto group and the N1-methyl groups of N1-methylinosine-37) within an anticodon loop structure of a tRNA molecule. We also describe the chemical synthesis of the phosphoramidite derivatives corresponding to N1-methylinosine and N1-methyl-2'-deoxyinosine for use in the automatic chemical synthesis of oligonucleotides containing N1-methylinosine and N1-methyl-2'-deoxyinosine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411130      PMCID: PMC1369811          DOI: 10.1017/s1355838299990118

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  53 in total

1.  Use of in vitro 32P labeling in the sequence analysis of nonradioactive tRNAs.

Authors:  M Silberklang; A M Gillum; U L RajBhandary
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

2.  The nucleotide sequence of two silk gland alanine tRNAs: implications for fibroin synthesis and for initiator tRNA structure.

Authors:  K U Sprague; O Hagenbüchle; M C Zuniga
Journal:  Cell       Date:  1977-07       Impact factor: 41.582

3.  [Methylation of inosine and uridylyl-(3'-5')inosine with dimethylsulfate].

Authors:  K H Scheit; A Holy
Journal:  Biochim Biophys Acta       Date:  1967-12-19

4.  Anti-inosine antibodies.

Authors:  H Inouye; S Fuchs; M Sela; U Z Littauer
Journal:  Biochim Biophys Acta       Date:  1971-07-29

5.  Specific labeling of 3' termini of RNA with T4 RNA ligase.

Authors:  T E England; A G Bruce; O C Uhlenbeck
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system.

Authors:  M Nishikai; M Reichlin
Journal:  Arthritis Rheum       Date:  1980-08

7.  Synthesis of RNA containing inosine: analysis of the sequence requirements for the 5' splice site of the Tetrahymena group I intron.

Authors:  R Green; J W Szostak; S A Benner; A Rich; N Usman
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

8.  Antibodies to yeast phenylalanine transfer ribonucleic acid are specific for the odd nucleoside ) in the anticodon loop.

Authors:  S Fuchs; A Aharonov; M Sela; F von der Haar; F Cramer
Journal:  Proc Natl Acad Sci U S A       Date:  1974-07       Impact factor: 11.205

Review 9.  Immune manifestations of inflammatory muscle disease.

Authors:  I N Targoff
Journal:  Rheum Dis Clin North Am       Date:  1994-11       Impact factor: 2.670

10.  Wide cross-species aminoacyl-tRNA synthetase replacement in vivo: yeast cytoplasmic alanine enzyme replaced by human polymyositis serum antigen.

Authors:  T L Ripmaster; K Shiba; P Schimmel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

View more
  7 in total

1.  Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens.

Authors:  William K Decker; Dongxia Xing; Sufang Li; Simon N Robinson; Hong Yang; David Steiner; Krishna V Komanduri; Elizabeth J Shpall
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

2.  The properties of a tRNA-specific adenosine deaminase from Drosophila melanogaster support an evolutionary link between pre-mRNA editing and tRNA modification.

Authors:  L P Keegan; A P Gerber; J Brindle; R Leemans; A Gallo; W Keller; M A O'Connell
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Post-synthetic and site-specific modification of endocyclic nitrogen atoms of purines in DNA and its potential for biological and structural studies.

Authors:  Raman Narukulla; David E G Shuker; Yao-Zhong Xu
Journal:  Nucleic Acids Res       Date:  2005-03-23       Impact factor: 16.971

Review 4.  Genome recoding by tRNA modifications.

Authors:  Francesca Tuorto; Frank Lyko
Journal:  Open Biol       Date:  2016-12       Impact factor: 6.411

5.  Toward an Understanding of Extracellular tRNA Biology.

Authors:  Adrian Gabriel Torres; Eulàlia Martí
Journal:  Front Mol Biosci       Date:  2021-04-15

6.  Importance of adenosine-to-inosine editing adjacent to the anticodon in an Arabidopsis alanine tRNA under environmental stress.

Authors:  Wenbin Zhou; Daniel Karcher; Ralph Bock
Journal:  Nucleic Acids Res       Date:  2013-01-25       Impact factor: 16.971

Review 7.  RNA editing in the forefront of epitranscriptomics and human health.

Authors:  Theodoulakis Christofi; Apostolos Zaravinos
Journal:  J Transl Med       Date:  2019-09-23       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.